CLDX Q4 2021 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$334,000-91.2% YoY

Gross Profit

-$14M-4294.6% margin

Operating Income

-$20M-6089.8% margin

Net Income

-$20M-6032.3% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+118.3%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$445M

Total Liabilities

$25M

Stockholders' Equity

$419M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$334,000	$4M	-91.2%
Gross Profit	-$14M	-$7M	-116.0%
Operating Income	-$20M	-$25M	+17.9%
Net Income	-$20M	-$22M	+8.0%

Revenue Segments

Contracts and grants

$332,00099%

Product development and licensing agreements

$2,0001%